Pretty sure Eman will get a rise out of the last paragraph:)
Mark J. Foley Mr. Foley has more than thirty years of leadership, commercial, operational, business development and investment experience in healthcare, 14 years of which have been in aesthetics. His prior experience includes ZELTIQ Aesthetics, Inc. (acquired by Allergan Inc.), RWI Ventures, U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly & Co.), Perclose (acquired by Abbott Laboratories) and Ventrica (acquired by Medtronic PLC). Mr. Foley’s tenure as CEO of ZELTIQ Aesthetics, Inc., a medical device company that developed non- invasive procedures for the reduction of unwanted fat, culminated in the acquisition of the company by Allergan for $2.5 billion in 2017, which created significant value for shareholders. Mr. Foley also has served on a number of other public and private company boards, providing him with relevant and valuable experience as our Board discharges its duties.
( We believe Mr. Foley is the right leader to steer the Company into its next phase of growth as the Company seeks to expand its market opportunity due to the breadth of his experience in the aesthetics industry, his prior executive leadership experiences in the healthcare space and “due to his track record of delivering stockholder value”).
Non- Independent Director since 2019 Independent Director 2017 - 2019 Positions Revance Therapeutics, Inc. • Chief Executive Officer (October 2019 – present) ZELTIQ Aesthetics • Chairman, President and CEO (2012 – 2017) RWI Ventures • Managing Member (2004 – 2018) Ventrica, Inc. • Founder, CEO (1998 – 2004)
Bullish
